Processa Pharmaceuticals: files 8-K on Vidya acquisition and Vidya financials

What happened Processa Pharmaceuticals filed an 8-K on Oct 5, 2026 that attached information reflecting the business of the company following the acquisition of Vidya and attached risks associated with the business following the acquisition. The filing also includes audited financial statements of Vidya as of and for the years ended Dec 31, 2025 and Dec 31, 2024 and unaudited interim condensed consolidated financial statements of Vidya as of and for the six months ended Jun 30, 2026 and Jun 30, 2025.

Key details

• Item 8.01: exhibits 99.3 (business section following the Vidya acquisition) and 99.4 (risk factors following the Vidya acquisition) are attached and incorporated by reference.
• Item 9.01: includes audited Vidya financial statements for years ended Dec 31, 2025 and Dec 31, 2024 and unaudited interim condensed consolidated statements for the six months ended Jun 30, 2026 and Jun 30, 2025.
• The filing uses the phrase "incorporated herein by reference" for the attached exhibits.

Why it may matter The filing reports Item 8.01 (other events) to provide the company’s business description and risk factors following its acquisition of Vidya, and Item 9.01 (financial statements and exhibits) to provide Vidya’s audited and interim financial statements. The filing does not show why the insider traded or why the company acted.